Company news

Cocrystal Pharma, Inc. news in 2025

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

December 18, 2025

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference

December 1, 2025

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

November 14, 2025

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

October 30, 2025

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

October 27, 2025

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

October 2, 2025

COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…

September 17, 2025

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

September 15, 2025

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

September 12, 2025

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

September 12, 2025

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

September 8, 2025

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

September 3, 2025

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

August 14, 2025

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

August 5, 2025

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

July 10, 2025

Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

June 5, 2025

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29, 2025

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

May 28, 2025

COCP: Topline Results for High-Dose Cohort from Phase 1 Trial of CDI-988 Expected in 2Q25…

May 27, 2025

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15, 2025

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

April 24, 2025

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

April 16, 2025

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

March 31, 2025

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

March 6, 2025

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

January 7, 2025

Decks in 2025